
Sign up to save your podcasts
Or
What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Harvard Business School professors Richard Hamermesh and Kathy Giusti discuss their case — entitled “Intermountain Healthcare: Pursuing Precision Medicine” — and its connections to their work with the Kraft Precision Medicine Accelerator.
4.5
183183 ratings
What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Harvard Business School professors Richard Hamermesh and Kathy Giusti discuss their case — entitled “Intermountain Healthcare: Pursuing Precision Medicine” — and its connections to their work with the Kraft Precision Medicine Accelerator.
1,828 Listeners
1,157 Listeners
382 Listeners
1,118 Listeners
105 Listeners
1,402 Listeners
744 Listeners
107 Listeners
169 Listeners
36 Listeners
790 Listeners
635 Listeners
219 Listeners
73 Listeners
85 Listeners
151 Listeners
77 Listeners